Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) had its price target lowered by Chardan Capital from $10.00 to $5.50 in a research note published on Wednesday morning. The brokerage currently has a buy rating on the stock.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 2.25 on Wednesday. The company’s market capitalization is $147.38 million. The stock has a 50 day moving average of $3.88 and a 200 day moving average of $4.58. Aralez Pharmaceuticals has a 12 month low of $2.05 and a 12 month high of $6.80.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative net margin of 211.76% and a negative return on equity of 65.67%. The business earned $20 million during the quarter, compared to analyst estimates of $21.86 million. During the same period in the previous year, the business posted ($0.40) EPS. The business’s revenue for the quarter was up 233.3% compared to the same quarter last year. Equities analysts anticipate that Aralez Pharmaceuticals will post ($1.07) EPS for the current fiscal year.
Your IP Address:
In other Aralez Pharmaceuticals news, CEO Adrian Adams purchased 500,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Wednesday, March 15th. The stock was acquired at an average price of $2.46 per share, with a total value of $1,230,000.00. Following the transaction, the chief executive officer now owns 3,569,230 shares in the company, valued at approximately $8,780,305.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur S. Kirsch purchased 45,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Wednesday, March 15th. The stock was acquired at an average cost of $2.27 per share, with a total value of $102,150.00. Following the transaction, the director now owns 149,109 shares in the company, valued at approximately $338,477.43. The disclosure for this purchase can be found here. In the last three months, insiders purchased 549,750 shares of company stock valued at $1,342,173. 6.77% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of the stock. Shufro Rose & Co. LLC increased its stake in Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock valued at $104,000 after buying an additional 5,000 shares during the last quarter. FNY Managed Accounts LLC increased its stake in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock valued at $286,000 after buying an additional 7,000 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Aralez Pharmaceuticals by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,224 shares of the company’s stock valued at $1,386,000 after buying an additional 7,014 shares during the last quarter. Integre Asset Management LLC increased its stake in Aralez Pharmaceuticals by 31.7% in the fourth quarter. Integre Asset Management LLC now owns 81,938 shares of the company’s stock valued at $361,000 after buying an additional 19,715 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Aralez Pharmaceuticals by 9.4% in the third quarter. Wells Fargo & Company MN now owns 260,769 shares of the company’s stock valued at $1,265,000 after buying an additional 22,441 shares during the last quarter. 44.01% of the stock is owned by institutional investors and hedge funds.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/chardan-capital-trims-aralez-pharmaceuticals-inc-arlz-target-price-to-5-50/1708584.html
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.